| Literature DB >> 35494966 |
Jayanthi Yadav1, Garima Goel2, Shashank Purwar3, Saurabh Saigal4, Ashwani Tandon5, Ankur Joshi6, Brinda Patel7, Sravan Js1, Mahaluxmi S1, Jitendra Singh8, Prem Shankar3, Arneet Arora1, Sarman Singh3.
Abstract
Background and objective Ever since its emergence in December 2019, coronavirus disease 2019 (COVID-19) has affected more than 220 million people worldwide, resulting in more than 45 million deaths. The present autopsy-based study was undertaken to understand the pathophysiology of the disease and correlate the histopathological and virological findings with the antemortem clinical and biochemical determinants. Methods In this prospective observational study, autopsies were carried out on 21 reverse transcription-polymerase chain reaction (RT-PCR)-proven COVID-19 patients who had died of the disease. The histopathological findings of tissue samples from lungs, liver, and kidneys collected during the autopsy were graded based on their presence or absence; if present, they were graded as either focal or diffuse. The findings were correlated with antemortem clinical and biochemical findings. Postmortem tissue RT-PCR analysis was conducted, and findings were compared with postmortem histopathological findings. Results There was multisystem involvement with the COVID-19 cases. The involvement of lungs was observed in most of the cases (90.4%). The presence of viral RNA was observed in all the organs including the liver (57.1%) and kidney (66.6%). An association was observed between antemortem biochemical parameters [aspartate aminotransferase (AST), alanine aminotransferase (ALT)] and the histopathological features in the liver. No correlation between the Sequential Organ Failure Assessment (SOFA) score recorded clinically and lung histopathology was observed; nor was there any correlation between blood urea-creatinine levels and kidney histopathology. Conclusions Our study shows that COVID-19 is a multisystemic disease and the mortality associated with it is likely to be multifactorial. Despite the presence of amplifiable severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in various organs, no association could be established between the clinical and histopathology findings. Neither the duration of hospitalization nor the duration of mechanical ventilation showed any correlation with the severity of histopathological findings in the lungs at autopsy.Entities:
Keywords: covid 19 autopsy; covid 19 clinioicopathologic features; covid 19 india; covid autopsy of liver and kidney; covid autopsy of lung; histopathology of lungs in covid 19; virology of tissues in covid 19
Year: 2022 PMID: 35494966 PMCID: PMC9041644 DOI: 10.7759/cureus.23538
Source DB: PubMed Journal: Cureus ISSN: 2168-8184
Comorbidities in deceased patients at the time of admission with COVID-19
COVID-19: coronavirus disease 2019
| Comorbidities | Number of cases (%) |
| Diabetes mellitus | 15 (71.4) |
| Hypertension | 13 (61.9) |
| Obesity | 6 (28.5) |
| Hypothyroidism | 4 (19) |
| Cardiac disease | 3 (14.2) |
| Cerebrovascular disease | 1 (4.7) |
| Hepatitis B | 1 (4.7) |
| Multiple myeloma | 1 (4.7) |
| Pancreatitis | 1 (4.7) |
| Chronic obstructive pulmonary disease | 1 (4.7) |
| Chronic Kidney disease | 1 (4.7) |
RT-PCR status of various organs tissue and swab collected during autopsy
RT-PCR: reverse transcription-polymerase chain reaction; +: positive; -: negative; NA: not available (as tissue was not collected during autopsy for RTPCR); R: rejected (as the amount of retrieved RNA was insufficient)
| Right lung tissue | Left lung tissue | Liver tissue | Kidney tissue | Nasopharyngeal swab | Tracheal swab | |
| 1 | NA | NA | NA | NA | + | + |
| 2 | + | + | + | + | + | + |
| 3 | + | + | - | + | + | + |
| 4 | + | + | + | + | + | + |
| 5 | + | + | - | - | + | - |
| 6 | + | + | - | + | + | + |
| 7 | + | + | + | + | + | + |
| 8 | - | - | - | + | + | - |
| 9 | + | + | - | R | - | - |
| 10 | + | + | + | + | + | + |
| 11 | + | + | + | + | + | + |
| 12 | + | + | + | + | + | + |
| 13 | - | - | + | + | + | + |
| 14 | - | - | + | + | + | + |
| 15 | + | + | + | + | + | + |
| 16 | + | + | - | - | + | + |
| 17 | + | + | + | + | + | + |
| 18 | + | - | - | - | + | + |
| 19 | + | + | + | - | - | + |
| 20 | - | - | - | + | - | + |
| 21 | + | + | - | + | + | + |
Clinical characteristics of deceased patients with COVID-19
COVID-19: coronavirus disease 2019; M: male; F: female; ARDS: acute respiratory distress syndrome; BA: bronchial asthma; CVA: cerebrovascular attack; CKD: chronic kidney disease; CAD: coronary artery disease; DM: diabetes mellitus; HTN: hypertension; HThy: hypothyroidism; MM: multiple myeloma; MODS: multiorgan dysfunction syndrome; Ob: obesity; SARI: severe acute respiratory infection; A: antibiotics; E: enoxaparin; S: steroid; R: remdesivir
| Case # | Age in years/sex | Comorbidities | Drugs used for treatment (C/S/R/A) | Hospitalization (days) | Duration of mechanical ventilation (days) | Cause of death | Death-to-autopsy interval (hours) |
| 1 | 58/M | HTN/Ob | E/S/R/A | 16 | 1 | Septic shock with COVID-19 pneumonia | 16.5 |
| 2 | 67/M | DM/HTN/CAD | E/A | 6 | 0 | Cardiopulmonary shock with COVID-19 pneumonia | 12.5 |
| 3 | 25/M | None | E/S/R/A | 14 | 14 | MODs with septic shock, ARDS with COVID-19 pneumonia | 8 |
| 4 | 30/M | Alcoholic pancreatitis | A | 2 | 2 | MODS with alcohol-induced pancreatitis and COVID-19 pneumonia | 19.5 |
| 5 | 60/M | DM/HTN/Ob | E/S/A | 39 | 4 | Septic shock with COVID-19 pneumonia | 12 |
| 6 | 30/M | Type-1 DM/Hep B | A | 4 | 0 | Type I DM with recurrent hypoglycemia with UTI with sepsis | 8.5 |
| 7 | 51/M | DM/HTN/CKD/HThy | E/S/R/A | 3 | 4 | MODS with septic shock | 11 |
| 8 | 75/M | DM/HTN/HThy/Ob | E/S/A | 6 | 4 | MODS with sepsis and COVID-19 pneumonia | 17 |
| 9 | 64/M | HTN | E/S/A | 9 | 1 | MODS with septic shock, ARDS, and COVID-19 pneumonia | 12 |
| 10 | 71/M | DM/CAD/MM | - | 0 | 0 | Sudden cardiac arrest, SARI with severe anemia and multiple myeloma | 5 |
| 11 | 62/M | DM/HTN/BA/Ob | E/S | 5 | 5 | Sepsis with MODS with ARDS and COVID-19 pneumonia | 14 |
| 12 | 79/M | DM/Ob | E/S | 8 | 1 | COVID-19 pneumonia with ARDS and septic shock | 18 |
| 13 | 45/F | DM/HTN/Ob | E/S/A | 2 | 2 | COVID-19 pneumonia | 14.5 |
| 14 | 75/M | DM/HTN | E/S/R/A | 8 | 1 | Septic shock with metabolic acidosis, COVID-19 pneumonia | 5 |
| 15 | 70/F | DM//HThy/Ob | E/S/A | 10 | 6 | Septic shock with MODS and COVID-19 pneumonia | 18 |
| 16 | 84/M | DM/HTN/CVA | E/S/R/A | 10 | 4 | Sepsis with MODS and COVID-19 pneumonia | 14.5 |
| 17 | 75/F | DM/HTN | E/S/A | 9 | 1 | Septic shock with COVID-19 pneumonia | 15 |
| 18 | 72/M | DM/HTN/Ob | E/S/R/A | 20 | 14 | Cardiac arrest with COVID-19 pneumonia | 3.5 |
| 19 | 64/F | DM//HThy/Ob | E/S/R/A | 18 | 6 | MODS with COVID-19 pneumonia | 6 |
| 20 | 60/F | HTN/Ob | E/S/A | 3 | 0 | Multiple injuries | 15 |
| 21 | 60/F | CAD/Ob | E/S/A | 4 | 4 | Sepsis with MODS and COVID-19 pneumonia | 6 |
Clinico-biochemical parameters of deceased patients with COVID-19
COVID-19: coronavirus disease 2019; SOFA: Sequential Organ Failure Assessment; CRP: C-reactive protein; AST: aspartate aminotransferase; ALT: alanine aminotransferase
| Case no. | SOFA score | Inflammatory markers | Liver function tests | Renal function tests | ||||
| CRP (<5 mg/l) | D-dimer of 0.1-0.5 (microgm/mL) | Bilirubin (initial/peak) of 0.3-1.2 mg/dL | AST (initial/peak) of <50 u/L | ALT (initial/peak) of <50 u/L | Creatinine (initial/peak) of 0.6-1.2 mg/dL | Urea (initial/peak) of 20-40 mg/dL | ||
| 1 | 3 | 316 | 0.36 | 1.2/1.2 | 22.82/148.17 | 25.99/130.4 | 1.4/1.6 | 32.1/78 |
| 2 | 8 | 7.63 | 1.06 | 0.4/0.5 | 37.6/37.6 | 27.5/40.5 | 1.4/1.8 | 44/75.3 |
| 3 | 10 | 285 | 0.69 | 0.72/1.8 | 47.8/393.8 | 42.9/91.4 | 1/3.1 | 26.4/216.8 |
| 4 | 14 | 590.36 | - | 12.5/15.8 | 760.4/760.4 | 183.9/183.9 | 5.4/5.6 | 199.1/254.3 |
| 5 | 8 | 192.07 | 1.77 | 0.99/1.25 | 41.27/378.6 | 76.9/108.3 | 1.2/1.2 | 43.9/79.1 |
| 6 | NA | 78.64 | - | 0.4/0.4 | 19.8/19.8 | 19.4/22.2 | 1.2/1.2 | 40.7/44.1 |
| 7 | 8 | 65.53 | - | 0.85/0.99 | 66.8/67.0 | 23.3/23.3 | 4/5.5 | 142.8/205.5 |
| 8 | 8 | 195.8 | 2.67 | 0.6/1.0 | 30/61.0 | 23.2/69.6 | 1.3/1.3 | 38.6/101.5 |
| 9 | 4 | 310 | 4.38 | 1.6/1.8 | 209.7/209.7 | 229.2/229.2 | 1.2/1.2 | 30.6/47.1 |
| 10 | NA | - | - | - | - | - | - | - |
| 11 | 6 | 323.11 | 2.09 | 0.8/0.8 | 48.5/67.8 | 23.9/33.4 | 1/4.2 | 41.4/193 |
| 12 | 10 | 169.46 | - | 0.5/0.6 | 46.9/47.3 | 30.6/41.8 | 0.9/1.3 | 58/119.2 |
| 13 | 6 | 96.07 | - | 3.18/3.45 | 162.1/379.6 | 66.9/70.3 | 1.7/2.2 | 44.2/70.1 |
| 14 | 2 | 338.37 | 14.21 | 0.5/0.9 | 60.1/60.1 | 54.3/54.3 | 0.9/0.9 | 33.7/69.4 |
| 15 | 6 | 204.68 | 1.84 | 0.4/0.5 | 77.5/106.6 | 48.4/75.1 | 1/2.3 | 34.3/189.2 |
| 16 | 4 | 25.41 | - | 0.3/1.6 | 40.9/127.1 | 21.7/56.5 | 1.1/1.1 | 62.6/97 |
| 17 | 7 | 149.23 | - | 0.5/1.2 | 88.2/88.2 | 35.3/39.7 | 1.4/1.4 | 67/201 |
| 18 | 4 | 307.3 | 0.73 | 0.6/0.97 | 30.31/118.4 | 26.5/109.6 | 2.6/3.7 | 40.4/333 |
| 19 | 4 | 96.53 | 0.57 | 0.6/1.1 | 48.3/104 | 21.1/49 | 0.7/1.02 | 24.4/73.6 |
| 20 | 2 | - | - | 0.3/0.6 | 50.2/50.2 | 49/49 | 0.7/0.8 | - |
| 21 | NA | - | - | 1.1/1.1 | 18.9/27.7 | 13.2/21.8 | 1.6/1.6 | - |
Histopathological findings in lungs of deceased patients with COVID-19
COVID-19: coronavirus disease 2019
| Histopathological findings in lungs | Absent (0) | Focal (1-25%) | Diffuse (>26%) | |
| Exudative phase | Capillary congestion | 0/21 | 7/21 | 14/21 |
| Interstitial and Intra-alveolar edema | 1/21 | 11/21 | 9/21 | |
| Alveolar hemorrhage | 11/21 | 6/21 | 4/21 | |
| Hyaline membrane | 8/21 | 7/21 | 6/21 | |
| Dilated alveolar duct/collapsed alveoli | 3/21 | 11/21 | 7/21 | |
| Fibrin thrombi | 2/21 | 13/21 | 6/21 | |
| Proliferative phase | Type 2 pneumocyte hyperplasia | 3/21 | 5/21 | 13/21 |
| Viral cytopathic effects | 3/21 | 5/21 | 13/21 | |
| Alveolar granulation tissue | 11/21 | 7/21 | 3/21 | |
| Multinucleate giant cells | 11/21 | 9/21 | 1/21 | |
| Fibrotic phase | Squamous metaplasia | 14/21 | 5/21 | 2/21 |
| Fibroblastic proliferation | 4/21 | 11/21 | 6/21 | |
| Capillary proliferation | 8/21 | 10/21 | 3/21 | |
| Pleural involvement | 16/21 | 5/21 | 0/21 | |
| Alveolar/interstitial inflammatory infiltrate | 1/21 | 8/21 | 12/21 |
Figure 1Haematoxylin and eosin-stained sections of lung parenchyma displaying various histopathological features
(A) Blood vessel showing fibrin thrombi (100x). (B) Presence of hyaline membranes in exudative phase (100x). (C) Pneumocyte hyperplasia with viral cytopathic effects in proliferative phase (400x). (D) Multinucleated giant cells (400x). (E) Squamous metaplasia (100x). (F) Fibrosis of the lung parenchyma in fibrotic phase (40x)
Figure 2Distribution of clinical severity (SOFA score) with histopathological findings in lungs
SOFA: Sequential Organ Failure Assessment
The histopathological changes observed in the liver of deceased patients with COVID-19 (n=21)
COVID-19: coronavirus disease 2019
| Histopathological finding in the liver (n=21) | Absent (0) | Focal (1-25%) | Diffuse (>26%) |
| Portal inflammation | 1 | 14 | 6 |
| Steatosis | 4 | 7 | 10 |
| Portal vein dilation | 5 | 14 | 2 |
| Herniated portal vein in periportal parenchyma | 12 | 8 | 1 |
| Lobular inflammation | 12 | 6 | 3 |
| Periportal abnormal vessels | 13 | 8 | 0 |
| Portal vein fibrosis | 15 | 6 | 0 |
| Fibrosis | 19 | 0 | 2 |
| Vascular thrombosis | 20 | 1 | 0 |
| Parenchymal necrosis | 20 | 0 | 1 |
Figure 3Haematoxylin and eosin-stained section of liver parenchyma displaying macrovesicular change (100x)
Figure 4Distribution of AST and ALT values with the histopathological findings in the liver
AST: aspartate aminotransferase; ALT: alanine aminotransferase
Comparison of median ALT and AST values with RT-PCR status in the liver tissue
AST: aspartate aminotransferase; ALT: alanine aminotransferase; RT-PCR: reverse transcription-polymerase chain reaction
| Liver enzymes | RT-PCR-positive | RT-PCR-negative |
| Median initial AST (IU) | 60.1 | 41.27 |
| Median peak AST (IU) | 67.75 | 127.06 |
| Median initial ALT (IU) | 30.63 | 42.82 |
| Median peak ALT (IU) | 48.95 | 91.39 |
Histopathological changes observed in kidneys of deceased patients with COVID-19
COVID-19: coronavirus disease 2019
| Histopathological changes in kidneys | ||||
| Tubules | Absent (0) | Focal (<50%) | Diffuse or severe (>50%) | Obscured by autolysis |
| Acute tubular necrosis | 2/21 | 4/21 | 12/21 | 3/21 |
| Glomeruli | Absent | 25% glomeruli | 26-50% glomeruli | >50% glomeruli |
| Glomerulosclerosis | 10/21 | 11/21 | 0/21 | 0/21 |
| Blood vessels and interstitium | Absent | Focal | Moderate | Diffuse |
| Fibrin thrombi in vessels | 18/21 | 3/21 | 0/21 | 0/21 |
| Arteriosclerosis | 10/21 | 11/21 | 0/21 | 0/21 |
| Interstitial inflammation | 6/21 | 15/21 | 0/21 | 0/21 |
Figure 5Histopathological findings of renal parenchyma
(A) Gross appearance of bilateral kidney in a single case showing congestion of the external surface. (B) Acute tubular necrosis (100x). (C) Acute tubular necrosis with sclerosed glomeruli (40x). (D) Sclerosed glomerulus in diabetic nephropathy (100x)
Figure 6Distribution of urea and creatinine with the histopathological findings in the liver
Figure 7Extent of the involvement of organs
(A) Extent of the involvement of lungs. (B) Extent of the involvement of the liver. (C) Extent of the involvement of kidneys